These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 28056565)

  • 1. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques.
    Greig JA; Nordin JML; White JW; Wang Q; Bote E; Goode T; Calcedo R; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2018 Jul; ():. PubMed ID: 29890905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
    Evans GL; Morgan RA
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
    Greig JA; Smith MK; Nordin JML; Goode T; Chroscinski EA; Buza EL; Schmidt N; Kattenhorn LM; Wadsworth S; Wilson JM
    Hum Gene Ther; 2022 Apr; 33(7-8):421-431. PubMed ID: 34652966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
    Nguyen GN; Lindgren JR; Seleme MC; Kafle S; Zander CB; Zheng XL; Sabatino DE
    J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.
    Burton M; Nakai H; Colosi P; Cunningham J; Mitchell R; Couto L
    Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12725-30. PubMed ID: 10535990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tolerance to human factor VIII in mice.
    Chao H; Walsh CE
    Blood; 2001 May; 97(10):3311-2. PubMed ID: 11342466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
    Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
    Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.